Potential risks associated with the proposed widespread use of Tamiflu

Environmental Health Perspectives

Volumn 115, Issue 1, 2007, Pages 102-106

  Singer, Andrew C ^a   Nunn, Miles A ^a   Gould, Ernest A ^a   Johnson, Andrew C ^a  

^a CENTRE FOR ECOLOGY AND HYDROLOGY   (United Kingdom)

Author keywords

Antiviral; Avian influenza; Bird flu; Catchment model; Oseltamivir; Pandemic; Pollution; Tamiflu; Viral resistance; Wildfowl

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; OSELTAMIVIR; ZANAMIVIR;

ARTICLE; BIODEGRADATION; CATCHMENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE COURSE; DRUG STRUCTURE; ECOTOXICITY; ENVIRONMENTAL EXPOSURE; FOWL; HUMAN; HYDROLOGY; INFLUENZA; INFLUENZA VIRUS; NONHUMAN; PANDEMIC; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RIVER; SEWAGE TREATMENT; UNITED KINGDOM; UNITED STATES; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSFORMATION; VIRUS TRANSMISSION; WATER CONTAMINATION;

ANIMALS; ANTIVIRAL AGENTS; BIRDS; DRUG RESISTANCE, VIRAL; GREAT BRITAIN; HUMANS; INFLUENZA A VIRUS; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, THEORETICAL; OSELTAMIVIR; RISK ASSESSMENT; RIVERS; UNITED STATES; WATER POLLUTANTS, CHEMICAL; WATER SUPPLY;

ANATIDAE; AVES; ORTHOMYXOVIRIDAE;

EID: 33845967479     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.9574     Document Type: Article

References (44)

1. Air GM, Laver WG. 1989. The neuraminidase of influenza virus. Proteins 6(4):341-356.
2. Alexander DJ. 2000. A review of influenza in different bird species. Vet Microbiol 74:3-13.
3. American Hospital Formulary Service. 2006. Oseltamivir. In: AHFS Drug Information, 8:1828: Available: http://www. ashp.org/ahfs/first_rel/ Revised-oseltamivir_nov2006.pdf [accessed 9 November 2006].
4. Anderson PD, D'Aco VJ, Shanahan P, Chapra SC, Buzby ME, Cunningham VL, et al. 2004. Screening analysis of human pharmaceutical compounds in U.S. surface waters. Environ Sci Technol 38(3):838-849.
5. Anderson RM, May RM. 1991. Infectious Diseases of Humans: Dynamics and Control. Oxford, UK:Oxford University Press.
6. Ashton D, Hilton M, Thomas KV. 2004. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci Total Environ 333(1-3):167-184.
7. Baker AT, Varghese JN, Laver WG, Air GM, Colman PM. 1987. Three-dimensional structure of neuraminidase of subtype N9 from an avian influenza virus. Proteins 2(2):111-117.
8. Bardsley-Elliot A, Noble S. 1999. Oseltamivir. Drugs 58(5):851-860.
9. BBC. 2006. Bird Flu: Country Preparations. Available: http://news.bbc.co.uk/1/hi/health/4380014stm [accessed 1 August 2006].
10. Bracken I, Martin D. 1989. The generation of spatial population distributions from census centroid data. Environ Plan A 21:537-543.
11. Colacino JM, Chirgadze NY, Garman E, Murti KG, Loncharich RJ, Baxter AJ, et al. 1997. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 236(1):66-75.
12. Cramer GM, Ford RA, Hall RL. 1978. Estimation of toxic hazard - a decision tree approach. J Cosmet Toxicol 16:255-276.
13. de Jong MD, Thanh TT, Khanh TH, Hien VM, Smith GJD, Chau NV, et al. 2005. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353(25):2667-2672.
14. EMEA (European Medicines Agency). 2005. Tamiflu: European Public Assessment Report. Scientific Discussion. Available: http://www.emea.eu.int/humandocs/PDFs/EPAR/tamiflu/136102en6.pdf [accessed 8 November 2006).
15. FAO (Food and Agriculture Organization). 2006. Caucasus, Balkans at High Risk for Deadly H5N1 Virus. Available: http://www.fao.org/newsroom/en/ news/2006/1000378/index.html [accessed 21 November 2006].
16. Ferguson NM, Cummings DAT, Fraser C, Cajka JC, Cooley PC, Burke DS. 2006. Strategies for mitigating an influenza pandemic [Letter]. Nature 442(7101):448-452.
17. Ferraris O, Kessler N, Lina B. 2005. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 68(1):43-48.
18. F. Hoffman-La Roche Ltd. 2006. Roche donates a further 2 million treatment courses of antiviral Tamiflu to the WHO for regional stockpiling. Available: http//www.roche.com/med-cor-2006-01-17 [accessed 9 November 2006].
19. GlaxoSmithKline. 2004. Relenza Diskhaler. Safety Data Sheet. SDS No. 110574. Version 06. Available: http://www.msdsgsk.com/11057406.pdf [accessed 8 November 2006].
20. He G, Massarella J, Ward P. 1999. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 37(6):471-484.
21. Holmes MGR, Young AR, Gustard AG, Grew R. 2002. A new approach to estimating mean flow in the UK. Hydrol Earth Syst Sci 6(4):709-720.
22. Hou BK, Ellis LBM, Wackett LP. 2004. Encoding microbial metabolic logic: predicting biodegradation. J Ind Microbiol Biotechnol 31(6):261-272.
23. Hughes MR. 2003. Regulation of salt gland, gut, and kidney interactions. Comp Biochem Physiol A 136:507-524.
24. Hughes MR, Sullivan TM, Bennett DC, Hwang H. 1999. Retrograde movement of urine into the gut of saline acclimated mallard ducks, Anas platyrhynchos. Can J Zool 77:342-346.
25. Hurt AC, Barr IG, Hartel G, Hampson AW. 2004. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res 62:37-45.
26. Johnson AC, Keller V, Williams RJ, Young A. 2006. A practical demonstration in modelling diclofenac and propranolol river water concentrations using a GIS hydrology model in a rural UK catchment. Environ Pollut doi:10.1016/j.envpol.2006.05.037 [Online 14 August 2006].
27. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, et al. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119(4):681-690.
28. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KHL, et al. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
29. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, et al. 1998. Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42(3):647-653.
30. McKimm-Breschkin J, Trivedi T, Hampson A, Hay A, Klimov A, Tashiro M, et al. 2003. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 47(7):2264-2272.
31. Mendel DB, Sidwell RW. 1998. Influenza virus resistance to neuraminidase inhibitors. Drug Resistance Updates 1(3):184-189.
32. Mendel DB, Tai CY, Escarpe PA, Li W, Sidwell RW, Huffman JH, et al. 1998. Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection. Antimicrob Agents Chemother 42(3):640-646.
33. Normile D. 2006. Avian influenza: wild birds only partly to blame in spreading H5N1. Science 312(5779):1451.
34. Palese P, Compans R. 1976. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 33(1):159-163.
35. Roche Laboratories. 2006. Tamiflu (Oseltamivir Phosphate) Capsules and for Oral Suspension. Nutley, NJ:Roche Laboratories. Available: http://www.rocheusa.com/products/tamiflu/pi.pdf [accessed 8 December 2006].
36. Russell CJ, Webster RG. 2005. The genesis of a pandemic influenza virus. Cell 122:368-371.
37. Sweeny DJ, Lynch G, Bidgood AM, Lew W, Wang K-Y, Cundy KC. 2000. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug Metab Dispos 28(7):737-741.
38. von Itzstein M, Wu W-Y, Kok GB, Pegg MS, Dyason JC, Jin B, et al. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. 363(6428):418-423.
39. Walter A, Hughes MR. 1978. Total body water volume and turnover rate in fresh water and sea water adapted glaucous-winged gulls, Larus glaucescens. Comp Biochem Physiol A Physiol 61(2):233-237.
40. Webster RG, Yakhno M, Hinshaw VS, Bean WJ, Murti KG. 1978. Intestinal influenza: replication and chracterisation of influenza viruses in ducks. Virology 84:268-278.
41. WHO (World Health Organization). 2006a. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. Available: http://www.who.int/csr/disease/avian_influenza/country/ cases_table_2006_11_13/en/index.html [accessed 30 November 2006].
42. WHO (World Health Organization). 2006b. Epidemiology of WHO-confirmed human cases of avian A(H5N1) infection. Wkly Epidemiol Rec 81(26):249-260. Available: http://www.who.int/wer/wer8126.pdf [accessed 30 November 2006].
43. WHO (World Health Organization) 2006c. WHO Pandemic Influenza Draft Protocol for Rapid Response and Containment. Available: http://www.who.int/entity/csr/disease/avian_influenza/guidelines/ protocolfinal30_05_06a.pdf [accessed 1 August 2006].
44. Young AR, Grew R, Holmes MGR. 2003. Low Flows 2000: a national water resources assessment and decision support tool. Water Sci Technol 48(10):119-126.